Abstract

The effect of metabolic characteristics on the prognosis of patients with metastatic renal cell carcinoma remains controversial. We investigated the associations between metabolic features of each individual and disease prognosis in patients with metastatic renal cell carcinoma. Data of 1,584 patients with metastatic renal cell carcinoma from a multi-institutional database were retrospectively analyzed. The entire cohort was stratified into three subgroups according to how many patients had abnormal metabolic features (hypertension, diabetes mellitus, and low body mass index). The Kaplan-Meier and Cox proportional analyses were performed to investigate the associations between abnormal metabolic features and disease prognosis. mThere were 465 subjects without any metabolic features, 995 with one or two, and 124 with three. When the survival outcomes were compared according to the number of metabolic features, patients with higher numbers of metabolic features had significantly shorter overall and cancer-specific survival than those with fewer metabolic features (all p values <0.05). The multivariate Cox analysis showed that the number of metabolic features was an independent predictor for shorter cancer-specific and overall survival (all p values < 0.05). When performing subgroup analysis according to the cellular type, significant results were only obtained among the clear cell subtype subgroup, with the association not being significant in the non-clear cell subtype cohort. Patients with more metabolic features had significantly worse survival outcomes than those with fewer metabolic features. However, the association was only statistically significant in patients with clear cell-type metastatic renal cell carcinoma.

Details

Title
The number of metabolic features as a significant prognostic factor in patients with metastatic renal cell carcinoma
Author
Dong, Yuk Hyeong 1   VIAFID ORCID Logo  ; Hwang Eu Chang 2   VIAFID ORCID Logo  ; Park, Jae Young 3 ; Jeong, Chang Wook 1 ; Song Cheryn 4 ; Seo, Seong Il 5 ; Seok-Soo, Byun 6 ; Kwak Cheol 1 ; Sung-Hoo, Hong 7 ; Kang Minyong 8 ; Chung, Jinsoo 9 ; Lee, Hakmin 6   VIAFID ORCID Logo 

 Seoul National University Hospital, Department of Urology, Seoul, Korea (GRID:grid.412484.f) (ISNI:0000 0001 0302 820X) 
 Chonnam National University Hwasun Hospital, Department of Urology, Hwasun, Korea (GRID:grid.411602.0) (ISNI:0000 0004 0647 9534) 
 Korea University Ansan Hospital, Korea University College of Medicine, Department of Urology, Ansan, Korea (GRID:grid.411134.2) (ISNI:0000 0004 0474 0479) 
 Asan Medical Center, University of Ulsan College of Medicine, Department of Urology, Seoul, Korea (GRID:grid.413967.e) (ISNI:0000 0001 0842 2126) 
 Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Urology, Seoul, Korea (GRID:grid.413967.e) 
 Seoul National University Bundang Hospital, Department of Urology, Seongnam, Korea (GRID:grid.412480.b) (ISNI:0000 0004 0647 3378) 
 College of Medicine, The Catholic University of Korea, Department of Urology, Seoul, Korea (GRID:grid.411947.e) (ISNI:0000 0004 0470 4224) 
 Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Urology, Seoul, Korea (GRID:grid.411947.e) 
 National Cancer Center, Department of Urology, Goyang, Korea (GRID:grid.410914.9) (ISNI:0000 0004 0628 9810) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2394524127
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.